Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H. Park, MD, Madhulika Shukla, Jose M Salcedo, Shreya Vemuri, Julie C Kinoshita, Marissa D Smith, Eric S. Winer, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 3998.

https://doi.org/10.1182/blood-2019-124478

Published: 2019

Journal Articles

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Fleur Cohen-Aubart, MD PhD, Ahmed Idbaih, MD PhD, Damien Galanaud, MD PhD, Bruno Law-Ye, MD, Jean-François Emile, MD PhD, Frédéric Charlotte, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Julien Haroche

Blood (2019) 134 (Supplement_1): 4272.

https://doi.org/10.1182/blood-2019-130606

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis

Gaurav Goyal, MBBS, Marie Hu, MD, Jithma P. Abeykoon, MD, Nora N Bennani, MD, Jay H Ryu, MD, Mithun Vinod Shah, MD PhD, Robert Vassallo, MD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 4189.

https://doi.org/10.1182/blood-2019-122334

Published: 2019

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Mirela Anghelina, Narendranath Epperla, MD MS, Kerry A. Rogers, MD, Ling Guo, MD, Qiuhong Zhao, MS, James S. Blachly, MD, David M. Lucas, PhD, Christopher C. Oakes, Gerard Lozanski, MD, Michael R. Grever, MD, Leslie A. Andritsos, MD

Blood (2018) 132 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2018-99-120043

Published: 2018

Journal Articles

Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing

Gaurav Goyal, MBBS, Robert Vassallo, MD, Karen L Rech, MD, Jay H Ryu, MD, Caroline J Davidge-Pitts, MBBCh, W Oliver Tobin, MBBCh, PhD, Matthew J Koster, MD, Nabila Nora Bennani, MD, Mithun Vinod Shah, MD PhD, Minetta C Liu, MD, Ronald S. Go, MD

Blood (2018) 132 (Supplement 1): 1112.

https://doi.org/10.1182/blood-2018-99-113196

Published: 2018

Journal Articles

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Benjamin H Durham, MD BS, Estibaliz Lopez-Rodrigo, MD, David H Abramson, MD, Jennifer Picarsic, MD, Alessandro Pastore, Diana Mandelker, MD PhD, Michael Francis Walsh, MD, Maria E Arcila, MD, Marc Ladanyi, MD, David Solit, MD, Michael F. Berger, PhD, David M. Hyman, MD, Michelle Ki, BSc, Ira Dunkel, MD, Frederic Geissmann, MD PhD, Eli L Diamond, MD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 49.

https://doi.org/10.1182/blood-2018-99-114248

Published: 2018

Journal Articles

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Xavier Troussard, MD, Laure Montané, Mourad Tiab, Carine Chaleteix, MD, Isabelle Grulois, Clothilde Lindet, Delphine Legoupil, Frederic Kohser, Diane Pannier, Frederic Maloisel, Pierre Bories, Céline AIT Oukhatar, Natalie Hoog Labouret, Jean-Yves Blay, MD PhD

Blood (2017) 130 (Supplement 1): 156.

https://doi.org/10.1182/blood.V130.Suppl_1.156.156

Published: 2017

Journal Articles

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Robert Kreitman, MD, Martin S. Tallman, MD, Tadeusz Robak, MD PhD, Steven Coutre, MD, Shannon Marshall, PhD, Jie Yang, PhD, Ira Pastan, MD, Nai Shun (Nancy) Yao, MD

Blood (2017) 130 (Supplement 1): 2765.

https://doi.org/10.1182/blood.V130.Suppl_1.2765.2765

Published: 2017

Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Blood (2017) 130 (Supplement 1): 2994.

https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994

Published: 2017

Journal Articles

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, MD, Monia Capponi, Achille Ambrosetti, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, MD, Luigi Rigacci, Gianluca Gaidano, MD PhD, Roberta Della Seta, Natalia Frattarelli, Paolo Falcucci, Giuseppe Visani, Robin Foà, MD, Brunangelo Falini, MD

Blood (2017) 130 (Supplement 1): 409.

https://doi.org/10.1182/blood.V130.Suppl_1.409.409

Published: 2017

Journal Articles

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Blood (2017) 130 (14): 1644–1648.

https://doi.org/10.1182/blood-2017-01-765107

Published: 2017

Includes: Supplemental data

Journal Articles

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Fleur Cohen Aubart, Jean-François Emile, Fabrice Carrat, Frédéric Charlotte, Neila Benameur, Jean Donadieu, Philippe Maksud, Ahmed Idbaih, Stéphane Barete, Khê Hoang-Xuan, Zahir Amoura, Julien Haroche

Blood (2017) 130 (11): 1377–1380.

https://doi.org/10.1182/blood-2017-03-771873

Published: 2017

Includes: Supplemental data

Journal Articles

Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights

Simone Weber, Marietta Truger, Wolfgang Kern, MD, Martin H van Vliet, PhD, Erik H van Beers, Niroshan Nadarajah, M.Sc., Manja Meggendorfer, PhD, Dennis Haupt, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2016) 128 (22): 4424.

https://doi.org/10.1182/blood.V128.22.4424.4424

Published: 2016

Journal Articles

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Yo-Ting Tsai, MS, Aparna Lakshmanan, PhD, Amy M. Lehman, MAS, Ellen J. Sass, Minh Tran, Fabienne McClanahan, MD PhD, Meixiao Long, MD PhD, Bonnie K. Harrington, DVM, Krista La Perle, DVM, PhD, Vincenzo Coppola, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Michael R. Grever, MD, David M. Lucas, PhD

Blood (2016) 128 (22): 1206.

https://doi.org/10.1182/blood.V128.22.1206.1206

Published: 2016

Journal Articles

Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, Achille Ambrosetti, MD, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, Gianluca Gaidano, MD PhD, Robin Foà, Brunangelo Falini

Blood (2016) 128 (22): 1214.

https://doi.org/10.1182/blood.V128.22.1214.1214

Published: 2016

Journal Articles

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Jeffrey Jones, MD MPH, Leslie Andritsos, MD, Robert J. Kreitman, MD, Farhad Ravandi, MD, Charles Schiffer, Timothy G. Call, MD, Gerard Lozanski, MD, Pamela Harris, MD, Jennifer Sexton, Amy S Ruppert, MAS, Michael R. Grever

Blood (2016) 128 (22): 1215.

https://doi.org/10.1182/blood.V128.22.1215.1215

Published: 2016

Journal Articles

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Blood (2016) 128 (22): 480.

https://doi.org/10.1182/blood.V128.22.480.480

Published: 2016

NARROW

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Tumor Mutational Burden and Other Immunotherapy Markers in Histiocytic Neoplasms Using Next Generation Sequencing

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

Negative Minimal Residual Disease Associated with Extended Response to Moxetumomab Pasudotox in Patients with Relapsed/Refractory Hairy Cell Leukemia: Long-Term Follow-up of Bone Marrow Immunohistochemistry Analyses from a Phase 1 Study

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)

Comprehensive Biologic Characterization of 99 Multiple Myeloma Patients Using Cytomorphology, FISH, Gene Expression Profiling and Mutation Screening Leads to Important Clinical and Therapeutic Insights

BRAF V600E Accelerates Disease Progression and Increases Immune Suppression in a Mouse Model of B-Cell Leukemia

Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-Basket Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only